COVID-19 Treatment: COVISHIELD (Neutralizing Antibody Cocktail)

Sorrento is developing a Neutralizing Antibody Cocktail to bind to distinct epitopes on SARS-CoV-2 Spike protein. The antibody cocktail potentially creates a high barrier to emergence of resistant variants in treated individuals. COVISHIELD mAbs Fc regions are engineered to eliminate interactions with host Fc receptors, thereby decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2 infection.